Not yet taking people in Franciaország1. fázis
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)
Key facts
- Where
- Saint-Herblain Cedex, FranciaországSee the site
- Phase
- 1. fázis
Where in Franciaország
- Institut De Cancerologie De L OuestSaint-Herblain Cedex, FranciaországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut De Cancerologie De L Ouest
- Trial code
- EU 2023-509729-33-00
- Record updated
- 2026. július 30.